Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial response to glucocorticoids.

Beela S Mathew1, Kathryn A Carson, Stuart A Grossman

  • 1Department of Radiation Oncology, Regional Cancer Center, Trivandrum, India.

Cancer
|December 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026
Same author

Persistent Delays in Diagnostic Evaluation Timeliness After an Abnormal Screening Mammogram in the Years following the Onset of the COVID-19 Pandemic.

Academic radiology·2026
Same author

Evaluating "Brain Permeability": A Critical Issue for the Development of Therapeutic Agents for Primary and Metastatic Brain Tumors.

Neuro-oncology·2026
Same author

Volumetric Analysis of Contrast Enhancement in Patients With Newly Diagnosed Glioblastomas.

Neurosurgery·2025
Same author

Using the BaByVFSS Impairment Profile to Characterize the Impact of Thin and Mildly Thick Liquid Consistencies on Validated Physiological Components of Swallowing in Bottle-Fed Children.

American journal of speech-language pathology·2025
Same author

Phase I study of NT-I7, a long-acting interleukin-7, in severe treatment-related lymphopenia following standard radiation and temozolomide for high-grade glioma.

Neuro-oncology advances·2025
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.

Cancer·2026
Same journal

Pediatric cancer survival in the United States from 2001 to 2021.

Cancer·2026
Same journal

Updates on intratumoral therapies in melanoma.

Cancer·2026
Same journal

Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O<sup>6</sup>-methylguanine-DNA methyltransferase glioblastoma: A single-arm, phase 2 study.

Cancer·2026
Same journal

Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel.

Cancer·2026
See all related articles

Initial glucocorticoid response in primary central nervous system lymphoma (PCNSL) patients predicts survival. A positive clinical or radiologic response significantly improves outcomes, highlighting its prognostic value.

Area of Science:

  • Neuro-oncology
  • Clinical Medicine
  • Pharmacology

Background:

  • Primary central nervous system lymphoma (PCNSL) prognosis is influenced by factors like age, performance status, and treatment modality.
  • PCNSL often shows temporary improvement with glucocorticoids before definitive therapy.
  • The prognostic impact of initial glucocorticoid response in PCNSL requires further investigation.

Purpose of the Study:

  • To evaluate the prognostic significance of clinical or radiologic response to initial glucocorticoid therapy in PCNSL patients.
  • To determine if early glucocorticoid response can predict patient survival.
  • To analyze the association between glucocorticoid response and known prognostic variables.

Main Methods:

  • Retrospective chart review of 76 HIV-negative adults with newly diagnosed PCNSL from 1980-2001.

Related Experiment Videos

  • Exclusion of 19 patients with uninformative medical records, leaving 57 for analysis.
  • Statistical analysis of survival data based on clinical and radiologic response to initial glucocorticoid treatment.

    • Main Results:

    • Median survival for all patients was 11.8 months.
    • Patients with clinical response to glucocorticoids had a median survival of 17.9 months versus 5.5 months for nonresponders (P=0.05).
    • Radiologic response to glucocorticoids correlated with significantly longer median survival (117.0 months vs. 5.5 months; P=0.001), even after adjusting for age and treatment.

    Conclusions:

    • Initial response to glucocorticoids is a significant prognostic factor in PCNSL.
    • Both clinical and radiologic responses to glucocorticoids indicate improved survival.
    • Glucocorticoid response assessment may aid in predicting outcomes for PCNSL patients.